These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 8341928)

  • 21. [Interleukin 10 in disseminated lupus erythematosus].
    Emilie D
    J Soc Biol; 2002; 196(1):19-21. PubMed ID: 12134628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The role of biotherapy in multiple myeloma].
    Petrucci MT; Tafuri A; Mandelli F
    Recenti Prog Med; 2000 Oct; 91(10):488-93. PubMed ID: 11072735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of human cytokines (IFN-gamma, TNF-alpha, IL-1 beta, IL-4) on porcine endothelial cells: induction of MHC and adhesion molecules and functional significance of these changes.
    Batten P; Yacoub MH; Rose ML
    Immunology; 1996 Jan; 87(1):127-33. PubMed ID: 8666424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AK-5 tumor-induced modulation of host immune function: upregulation of Th-1-type cytokine response mediates early tumor regression.
    Khar A; Kausalya S; Kamal MA
    Cytokines Mol Ther; 1996 Mar; 2(1):39-46. PubMed ID: 9384688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Up-to-date understanding of tuberculosis immunity].
    Mitsuyama M; Akagawa K; Kobayashi K; Sugawara I; Kawakami K; Yamamoto S; Okada Z
    Kekkaku; 2003 Jan; 78(1):51-5. PubMed ID: 12683337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence that an OX-2-positive cell can inhibit the stimulation of type 1 cytokine production by bone marrow-derived B7-1 (and B7-2)-positive dendritic cells.
    Gorczynski L; Chen Z; Hu J; Kai Y; Lei J; Ramakrishna V; Gorczynski RM
    J Immunol; 1999 Jan; 162(2):774-81. PubMed ID: 9916698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape.
    Rayman P; Uzzo RG; Kolenko V; Bloom T; Cathcart MK; Molto L; Novick AC; Bukowski RM; Hamilton T; Finke JH
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S81-7. PubMed ID: 10685665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and production of interleukin 10 in human myeloma cell lines.
    Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Yawata Y; Ueki A
    Br J Haematol; 2000 Dec; 111(3):835-42. PubMed ID: 11122145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2.
    Flieger D; Spengler U; Beier I; Sauerbruch T; Schmidt-Wolf I
    Cytokine; 2000 Jun; 12(6):756-61. PubMed ID: 10843759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-cytokine strategies.
    Dinarello CA
    Eur Cytokine Netw; 1992; 3(1):7-17. PubMed ID: 1581558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-2 receptor-directed therapies: antibody- or cytokine-based targeting molecules.
    Strom TB; Kelley VR; Murphy JR; Nichols J; Woodworth TG
    Adv Nephrol Necker Hosp; 1994; 23():347-56. PubMed ID: 8154364
    [No Abstract]   [Full Text] [Related]  

  • 32. Current stage of interleukin 2 receptor targeted therapy.
    Diamantstein T; Kupiec-Weglinski JW; Strom TB; Tilney NL
    Exp Clin Endocrinol; 1989 May; 93(2-3):114-24. PubMed ID: 2673804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Targeted therapy in inflammatory disease: cytokines].
    von Frenckell C; Malaise MG
    Rev Med Liege; 2012; 67 Spec No():22-8. PubMed ID: 22690482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Friendly fire: anti-cytokine antibodies elicited by microbes.
    Notarangelo LD; Holland SM
    Nat Med; 2016 Sep; 22(9):973-5. PubMed ID: 27603131
    [No Abstract]   [Full Text] [Related]  

  • 35. Agents against cytokine synthesis or receptors.
    Yamagata T; Ichinose M
    Eur J Pharmacol; 2006 Mar; 533(1-3):289-301. PubMed ID: 16457805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
    Xiang J
    Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
    Pallua N; Low JF; von Heimburg D
    Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
    Wagner B; Robeson J; McCracken M; Wattrang E; Antczak DF
    Vet Immunol Immunopathol; 2005 May; 105(1-2):1-14. PubMed ID: 15797470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Anti-cytokines and anti-cytokine receptors].
    Dantal J; Giral M; Soulillou JP
    Rev Prat; 1993 Mar; 43(5):586-9. PubMed ID: 8341928
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.